Owens Ryan E, Twilla Jennifer D, Self Timothy H, Alshaya Abdulrahman I, Metra Carlvin J, Cummings Carolyn, Oliphant Carrie S
1 Department of Pharmacy Practice, Wingate University School of Pharmacy, Hendersonville, NC, USA.
2 Department of Pharmacy, Methodist University Hospital, Memphis, TN, USA.
J Pharm Pract. 2018 Feb;31(1):40-45. doi: 10.1177/0897190017696951. Epub 2017 Mar 10.
Raised resting heart rate (HR), >70 beats per minute (bpm), has been shown to be a risk factor for adverse cardiovascular outcomes and hospital readmissions, specifically in patients with heart failure with reduced ejection fraction (HF rEF). Given their mortality benefit, β-blockers are recommended in HF rEF, with a goal to titrate to a maximum tolerated dose rather than a specific HR target.
To determine the impact of optimal HR control achievement prior to hospital discharge on hospital readmissions in patients with HF rEF receiving β-blockade.
A retrospective study of patients admitted to 5 adult hospitals within a large urban health-care system, between 2013 and 2015, was conducted. Patients were identified via International Classification of Diseases, Ninth Revision ( ICD-9) coding for acute on chronic HF rEF.
Of the 225 patients included, 20% achieved optimal HR control (n = 46, HR <70 bpm; n = 179, HR ≥70 bpm) and only 15% received β-blocker titration during hospital admission. Of note, 25% of patients receiving ≥50% target dose (n = 79) and 28% receiving 100% target dose (n = 39) achieved optimal HR control. At 30 days, patients with an HR <70 bpm versus HR ≥70 bpm exhibited similar readmission rates (9% vs 11%, respectively; P > .99) and ED visits (11% vs 8%, respectively; P = .57).
Readmission rates were similar among patients with HF rEF despite the majority failing to achieve optimal HR control from β-blockade. However, β-blocker dosing remains suboptimal relative to guideline-recommended target doses. Opportunities exist for inpatient clinicians to optimize β-blockade in an attempt to achieve HR control.
静息心率(HR)升高,>70次/分钟(bpm),已被证明是不良心血管结局和再次入院的危险因素,特别是在射血分数降低的心力衰竭(HF rEF)患者中。鉴于β受体阻滞剂对死亡率有益,推荐用于HF rEF患者,目标是滴定至最大耐受剂量而非特定的心率目标。
确定出院前达到最佳心率控制对接受β受体阻滞剂治疗的HF rEF患者再次入院的影响。
对2013年至2015年期间在一个大型城市医疗系统内的5家成人医院住院的患者进行回顾性研究。通过国际疾病分类第九版(ICD-9)编码确定慢性HF rEF急性发作患者。
纳入的225例患者中,20%达到最佳心率控制(n = 46,HR <70 bpm;n = 179,HR≥70 bpm),住院期间仅15%接受了β受体阻滞剂滴定。值得注意的是,接受≥50%目标剂量(n = 79)的患者中有25%和接受100%目标剂量(n = 39)的患者中有28%达到了最佳心率控制。在30天时,HR <70 bpm与HR≥70 bpm的患者再次入院率相似(分别为9%和11%;P>.99),急诊就诊率也相似(分别为11%和8%;P = 0.57)。
尽管大多数HF rEF患者未能通过β受体阻滞剂实现最佳心率控制,但再次入院率相似。然而,相对于指南推荐的目标剂量,β受体阻滞剂的给药仍未达到最佳。住院临床医生有机会优化β受体阻滞剂的使用以实现心率控制。